Non-Viral Drug Delivery Systems Market SIZE AND SHARE ANALYSIS - GROWTH TRENDS AND FORECASTS (2024 - 2031)
Non-Viral Drug Delivery Systems Market is Segmented By Type of Molecule Delivered (Small Molecules, Biologics), By Type of Biologic Delivered (RNAi/mRNA, DNA Oligonucleotides, Antibodies, Proteins/Peptides), By Geography (North America, Latin America, Asia Pacific, Europe, Middle East, and Africa). The report offers the value (in USD billion) for the above-mentioned segments.
Non-Viral Drug Delivery Systems Market Size
Market Size in USD
CAGR13.8%
| Study Period | 2024 - 2031 |
| Base Year of Estimation | 2023 |
| CAGR | 13.8% |
| Market Concentration | Medium |
| Major Players | Arcturus Therapeutics, Bio-Path Holdings, CureVac, Entos Pharmaceuticals, eTheRNA Immunotherapies |
please let us know !
Non-Viral Drug Delivery Systems Market Analysis
The non-viral drug delivery systems market is estimated to be valued at USD 8.1 Bn in 2024 and is expected to reach USD 20.1 Bn by 2031, growing at a compound annual growth rate (CAGR) of 13.8% from 2024 to 2031. Recent technological advancements have enabled improved targetability and delivery of therapeutics. Furthermore, the growing prevalence of chronic diseases and increasing demand for advanced drug delivery systems are contributing to the growth of the non-viral drug delivery systems market.
The market is witnessing positive trends with the increasing demand for advanced drug delivery systems and investments in R&D activities. The growing need to improve the bioavailability and solubility of drugs is further propelling the demand for non-viral drug delivery systems. Additionally, supportive government policies and emphasis on drug development are expected to contribute to the strong market growth over the forecast period.